Deferoxamine

From WikiMD's WELLNESSPEDIA

(Redirected from Desferal)

Information about Deferoxamine[edit]

Deferoxamine is a parenterally administered iron chelating agent used to treat transfusion related chronic iron overload. 


Liver safety of Deferoxamine[edit]

Deferoxamine rarely causes serum aminotransferase elevations during therapy and has not been convincingly linked to instances of clinically apparent liver injury.  

== Mechanism of action of Deferoxamine ==  Deferoxamine (de” fer ox’ a meen) is parenterally administered iron chelating agent that binds iron with a high affinity and zinc and copper to a lesser extent.  In clinical trials in patients with transfusion related iron overload, deferoxamine therapy lowered both circulating and tissue (cardiac, liver) iron levels and these reductions were maintained with long term subcutaneous infusions. 

FDA approval information for Deferoxamine[edit]

Deferoxamine was approved for use in the United States in 1968 and current indications are for patients with transfusion related chronic iron overload as well as for acute iron overdose or intoxication. 

Dosage and administration for Deferoxamine[edit]

Deferoxamine is available in vials of 500 and 2000 mg for intravenous, intramuscular or subcutaneous administration generically and under the brand name Desferal.  The subcutaneous routine is used most often for chronic iron overload and the typical dose is 1000 to 2000 mg per day (20 to 40 mg/kg/day) for 5 to 7 days a week given by continuous infusion over 8 to 24 hours. 

Side effects of Deferoxamine[edit]

Side effects include injection site pain and infection, hypersensitivity reactions, arthralgias, myalgias, fever, headache, nausea and abdominal pain.  Rare, but potentially severe adverse events of deferoxamine therapy include hearing and visual loss, acute renal failure and severe hypersensitivity reactions.

Arsenic Chelators

Copper Chelators (for Wilson Disease)

Iron Chelators

Lead Chelators

Mercury Chelators

Deferoxamine[edit]

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.